TransMedics Group is trading 4% up at $79.75 as traders position themselves ahead of the company's Q2 2026 earnings report scheduled for August 04, 2026.
- The stock is benefiting from a positive broader market backdrop, with major U.S. indices trading modestly higher.
- A shift toward risk-on sentiment in growth and healthcare sectors is providing additional support for the upward move.